SCHEMBL22816232

SCHEMBL22816232

COc1ccc(Cn2nnc(C(=O)O)c2Oc2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
ALOX15 P16050 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
AKR1C3 P42330 5/20 0.45
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
POLB P06746 2/20 0.42
MAPT P10636 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
PTGER4 P35408 1/20 0.42
LMNA P02545 2/20 0.42
AKR1C2 P52895 2/20 0.41
CYP1A2 P05177 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPBWR1 P48145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22816581 0.97 TP53 (0.47) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL22815682 0.91 AKR1C3 (0.47) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL22816144 0.90 TP53 (0.43) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL23484637 0.89 NPBWR1 (0.53) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL22816226 0.89 CYP19A1 (0.47) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL22816662 0.88 MARS1 (0.43) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL22816200 0.87 POLB (0.42) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL21296920 0.86 NPBWR1 (0.51) L3MBTL1ALOX15MEN1KMT2AAKR1C3
SCHEMBL22815655 0.86 NPBWR1 (0.51) TP53L3MBTL1ALOX15MEN1KMT2A
SCHEMBL21296928 0.85 ALOX15 (0.49) L3MBTL1ALOX15MEN1KMT2AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT TP53 2420/4885L3MBTL1 1830/4885ALOX15 176/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT TP53 2420/4885L3MBTL1 1830/4885ALOX15 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.